PROCEEDINGS AGAINST PCT, WPG and FREQ
NEW YORK, NY / ACCESSWIRE / June 11, 2021 / Jakubowitz Law announces that securities fraud class actions have been brought on behalf of shareholders of the following publicly traded companies who purchased shares during the remedy periods listed below. The shareholders interested in representing the category of injured shareholders have until the deadline for the main plaintiff to file a complaint with the court. Your ability to participate in any recovery does not require you to serve as the principal applicant. For more details and to speak with our company at no cost or obligation, follow the links below.
PureCycle Technologies, Inc. (NASDAQ: PCT)
CONTACT JAKUBOWITZ ABOUT PCT:
Course period: November 16, 2020 – May 5, 2021
Lead Applicant Deadline : July 12, 2021
The complaint filed alleges that the defendants made materially false and / or misleading statements and / or failed to disclose that: (i) PureCycle technology licensed from Procter & Gamble is unproven and presents serious problems, even at the laboratory scale; (ii) the challenges posed by the availability and competition for the raw materials necessary for the commercialization of the licensed technology are significant; (iii) PureCycle’s financial projections are baseless; and (iv) accordingly, the Company’s public statements were materially false and misleading at all material times.
Washington Prime Group, Inc. (NYSE: WPG)
CONTACT JAKUBOWITZ ABOUT WPG:
Course period: November 5, 2020 – March 4, 2021
Lead Applicant Deadline : July 23, 2021
The complaint filed alleges that the defendants made materially false and / or misleading statements and / or failed to disclose that: (1) WPG’s financial condition was deteriorating significantly; (2) as a result, there was considerable uncertainty as to the Company’s ability to meet its capital structure obligations as they became due; and (3) as a result of the foregoing, the Defendants’ positive statements regarding the business, operations and prospects of the Company were substantially misleading and / or lacked reasonable basis.
Frequency Therapeutics, Inc. (NASDAQ: FREQ)
CONTACT JAKUBOWITZ ABOUT FREQ:
Course period: November 16, 2020 – March 22, 2021
Lead Applicant Deadline : August 2, 2021
The complaint filed alleges that the defendants made materially false and / or misleading statements and / or failed to disclose that:. Despite the disappointing results, the company continued to conduct the Phase 2a study while issuing positive statements in earnings calls, press releases, SEC filings, and pharmaceutical presentations on the potential of FX- 322. These statements significantly misled the market and artificially inflated the value of Frequency’s common stock.
Jakubowitz Law is vigorous in pursuing justice for shareholders who have been victims of securities fraud. Lawyer advertising. Past results do not guarantee similar results.
1140 Avenue of the Americas
New York, New York 10036
T: (212) 867-4490
Fax : (212) 537-5887
SOURCE: Jakubowitz Law
See the source version on accesswire.com: